Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients

Lupus

Volumn 19, Issue 1, 2010, Pages 27-33

  Ribeiro, G G ^a   Bonfa E ^a   Neto, R Sasdeli ^a   Abe, J ^a   Caparbo, V F ^a   Borba, E F ^a   Lopes, J B ^a   Gebrim, E ^a   Pereira, R M R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Bone mineral density; Calcification; Coronary artery; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTERY CALCIFICATION; ARTICLE; BODY MASS; BONE DENSITY; CARDIOVASCULAR RISK; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG PULSE THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY INSUFFICIENCY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BONE DENSITY; CALCINOSIS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TIME FACTORS;

EID: 74849126013     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309345778     Document Type: Article

References (55)

1. Uramoto KM, Michet CJ Jr, Thumboo J., et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999 ; 42: 46-50.
2. Esdaile JM, Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001 ; 44: 2331-2337.
3. Souza AW, Hatta FS, Miranda F., Sato EI Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005 ; 123: 137-142.
4. Asanuma Y., Oeser A., Shintani AK, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 ; 349: 2407-2415.
5. Rosner S., Ginzler EM, Diamonk HS, et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982 ; 25: 612-617.
6. Urowitz MB, Gladman DD Accelerated atheroma in lupus-background. Lupus 2000 ; 9: 161-165.
7. Manzi S., Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997 ; 145: 408-415.
8. Bruce IN, Urowitz MB, Gladman DD, Ibanez D., Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. The Toronto risk factor study. Arthritis Rheum 2003 ; 48: 3159-3167.
9. El-Magadmi M., Bodill H., Ahmad Y., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004 ; 110: 399-404.
10. Feldt JMV, Scalzi LV, Cucchiara AJ, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006 ; 54: 2220-2227.
11. Manzi S., Selzer F., Sutton-Tyrrell K., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 51-60.
12. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology 2000 ; 39: 353-359.
13. Goodman WG, Goldin J., Kuizan BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 ; 342: 1478-1483.
14. Ravera M., Paoletti E. Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease. Ital Heart J Suppl 2004 ; 5: 436-444.
15. Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 ; 349: 2399-2406.
16. Danilevicius CF, Lopes JB, Pereira RM Bone metabolism and vascular calcification. Braz J Med Biol Res 2007 ; 40: 435-442.
17. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M., Dobnig H. Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int 2007 ; 18: 251-259.
18. Tintut Y., Parhami F., Tsingotjidou A., Tetradis S., Territo M., Demer LL 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)- dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002 ; 277: 14221-14226.
19. Min H., Morony S., Sarosi I., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000 ; 192: 463-474.
20. Naves M., Rodríguez-García M., Díaz-LÓpez JB, GÓmez-Alonso C., Cannata-Andía JB Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008 ; 19: 1161-1166.
21. Samelson EJ, Cupples LA, Broe KE, Hannan MT, O Donnell CJ, Kiel DP Vascular calcification in middle age and long-term risk of hip fracture: the Framingham Study. J Bone Miner Res 2007 ; 22: 1449-1454.
22. Hak AE, Pols HA, van Hemert AM, Hofman A., Witteman JC Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000 ; 20: 1926-1931.
23. Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997 ; 40: 1725.
24. Telles RW, Lanna CCD, Ferreira GA, Souza AJ, Navarro TP, Ribeiro AL Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting. Lupus 2008 ; 17: 105-113.
25. Nelson HD Menopause. Lancet 2008 ; 371: 760-770.
26. Levey AS, Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003 ; 139: 137-147.
27. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH the Committee on Prognosis Studies in SLE. (1992). Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992 ; 35: 630-641.
28. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996 ; 39: 363-369.
29. Siedel J., HÄgele EO, Ziegenhorn J., Wahlefeld AW Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983 ; 29: 1075-1080.
30. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982 ; 28: 2077-2080.
31. Warnick GR, Cheung NC, Albers JJ Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem 1979 ; 25: 596-604.
32. Friedwald WT, Levy RI, Fredrickson DS Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 ; 18: 499-502.
33. Tan EM, Peebles C. Quantification of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination. In: Rose NR, Friedman H (eds), Manual of clinical immunology, 2 nd edn. Washington, DC: American Society of Microbiology ; 1980. pp. 866-870.
34. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986 ; 146: 2153-2156.
35. Khan AA, Bachrach L., Brown JP, et al. Standards and guidelines for performing central dual-energy X-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom 2004 ; 7: 51-63.
36. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M. Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990 ; 15: 827-832.
37. Selzer F., Sutton-Tyrrel K., Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004 ; 50: 151-159.
38. Maturana MA, Irigoyen MC, Spritzer PM Menopause, estrogens, and endothelial dysfunction: current concepts. Clinics 2007 ; 62: 77-86.
39. Wong ND, Budoff MJ, Pio J., Detrano RC Coronary calcium and cardiovascular event risk: evaluation by age- and sex-specific quartiles. Am Heart J 2002 ; 143: 456-459.
40. Kiani AN, Magder L., Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008 ; 35: 1-7.
41. Janowitz WR, Agatston AS, Kaplan G., Viamonte M. Differences in prevalence and extend of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am J Cardiol 1993 ; 72: 247-254.
42. Hoff JA, Chomka EV, Krainik AJ, Daviglus M., Rich S., Kondos GT Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. Am J Cardiol 2001 ; 87: 1335-1339.
43. Asanuma YU, Chung CP, Oeser A., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006 ; 33: 539-545.
44. Manger K., Kusus M., Forster C., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003 ; 62: 846-850.
45. Lakoski SG, Greenland P., Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as low risk based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2007 ; 167: 2437-2442.
46. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997 ; 6: 533-539.
47. Bruce IN, Urowitz MB, Gladman DD, Hallett DC Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999 ; 26: 2137-2143.
48. Doria A., Shoenfeld Y., Wu R., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003 ; 62: 1071-1077.
49. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 1994 ; 79: 950-954.
50. Nordin BE, Chatterton BE, Schultz CG, Need AG, Horowitz M. Regional bone mineral density interrelationships in normal and osteoporotic postmenopausal women. J Bone Miner Res 1996 ; 11: 849-856.
51. Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford) 2005 ; 44: 1503-1506.
52. Ramsey-Goldman R., Manzi S. Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. Arthritis Rheum 2001 ; 44: 2338-2341.
53. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 ; 89: 309-319.
54. Schoppet M., Preissner KT, Hofbauer LC RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002 ; 22: 549-553.
55. Bekker PJ, Holloway D., Nakanishi A., Arrighi M., Leese PT, Dunstan CR The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 ; 16: 348-360.